Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-dopa PET in Parkinson's disease
Identifieur interne : 003E87 ( Main/Exploration ); précédent : 003E86; suivant : 003E88Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-dopa PET in Parkinson's disease
Auteurs : F. J. G. Vingerhoets [Canada] ; M. Schulzer ; T. J. Ruth ; J. E. Holden ; B. J. SnowSource :
- The Journal of nuclear medicine : (1978) [ 0161-5505 ] ; 1996.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Analysis of Variance, Brain (diagnostic imaging), Case-Control Studies, Diagnosis, Dihydroxyphenylalanine (analogs & derivatives), Emission tomography, Experimental study, Female, Fluorine Radioisotopes, Follow-Up Studies, Human, Humans, In vivo, Male, Measurement method, Middle Aged, Parkinson Disease (diagnostic imaging), Parkinson Disease (epidemiology), Parkinson disease, Positron, Reproducibility of Results, Time Factors, Tomography, Emission-Computed (methods).
- MESH :
- chemical , analogs & derivatives : Dihydroxyphenylalanine.
- diagnostic imaging : Brain, Parkinson Disease.
- epidemiology : Parkinson Disease.
- methods : Tomography, Emission-Computed.
- Analysis of Variance, Case-Control Studies, Female, Fluorine Radioisotopes, Follow-Up Studies, Humans, Male, Middle Aged, Reproducibility of Results, Time Factors.
Abstract
Fluorine-18-fluorodopa (F-Dopa) PET assesses the integrity of the nigrostriatal dopaminergic neurons in Parkinson's disease. It has been used in longitudinal studies to measure the progression of Parkinson's disease and the effects of medications and intracerebral transplants. The significance of changes in PET indices in such studies depends largely on the reproducibility of the F-Dopa PET measurements. Methods : We performed repeated F-Dopa PET scans in 12 subjects with Parkinson's disease (between Hoehn and Yahr stages I and III) to measure scan-to-scan variations. Data were analyzed using five methods comprising two sets of regions of interest (ROIs) (total striatum and substriatal), the striatum-to-cortex ratio and two graphical methods (one using plasma radioactivity, the other using cortical radioactivity as the input function). We also studied the effectiveness of each method in discriminating between patients with Parkinson's disease and normal subjects using data obtained from a similar study in 10 normal subjects. Results : We found reliability coefficients between 66% and 93% ; the scan-to-scan intrasubject standard deviation ranged from 2% to 16% of the mean value depending on the method of analysis and the size of the ROls. All methods discriminated significantly between patients with Parkinson's disease and normal subjects. The ability to discriminate, as reflected by the intergroup/intragroup ratio of variance, ranged from 2 to 18. Conclusion : These results permit selection of the best method of analysis for studies of nigrostriatal dopaminergic function.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000F36
- to stream PascalFrancis, to step Curation: 000F87
- to stream PascalFrancis, to step Checkpoint: 000E12
- to stream Main, to step Merge: 004578
- to stream PubMed, to step Corpus: 001884
- to stream PubMed, to step Curation: 001884
- to stream PubMed, to step Checkpoint: 001884
- to stream Ncbi, to step Merge: 002541
- to stream Ncbi, to step Curation: 002541
- to stream Ncbi, to step Checkpoint: 002541
- to stream Main, to step Merge: 004349
- to stream Main, to step Curation: 003E87
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-dopa PET in Parkinson's disease</title><author><name sortKey="Vingerhoets, F J G" sort="Vingerhoets, F J G" uniqKey="Vingerhoets F" first="F. J. G." last="Vingerhoets">F. J. G. Vingerhoets</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre and TRIUMF, University of British Columbia</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3></inist:fA14><country>Canada</country><wicri:noRegion>Vancouver, British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Schulzer, M" sort="Schulzer, M" uniqKey="Schulzer M" first="M." last="Schulzer">M. Schulzer</name></author><author><name sortKey="Ruth, T J" sort="Ruth, T J" uniqKey="Ruth T" first="T. J." last="Ruth">T. J. Ruth</name></author><author><name sortKey="Holden, J E" sort="Holden, J E" uniqKey="Holden J" first="J. E." last="Holden">J. E. Holden</name></author><author><name sortKey="Snow, B J" sort="Snow, B J" uniqKey="Snow B" first="B. J." last="Snow">B. J. Snow</name></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">96-0268079</idno><date when="1996">1996</date><idno type="stanalyst">PASCAL 96-0268079 INIST</idno><idno type="RBID">Pascal:96-0268079</idno><idno type="wicri:Area/PascalFrancis/Corpus">000F36</idno><idno type="wicri:Area/PascalFrancis/Curation">000F87</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000E12</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000E12</idno><idno type="wicri:doubleKey">0161-5505:1996:Vingerhoets F:reproducibility:and:discriminating</idno><idno type="wicri:Area/Main/Merge">004578</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:8772636</idno><idno type="wicri:Area/PubMed/Corpus">001884</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001884</idno><idno type="wicri:Area/PubMed/Curation">001884</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001884</idno><idno type="wicri:Area/PubMed/Checkpoint">001884</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001884</idno><idno type="wicri:Area/Ncbi/Merge">002541</idno><idno type="wicri:Area/Ncbi/Curation">002541</idno><idno type="wicri:Area/Ncbi/Checkpoint">002541</idno><idno type="wicri:doubleKey">0161-5505:1996:Vingerhoets F:reproducibility:and:discriminating</idno><idno type="wicri:Area/Main/Merge">004349</idno><idno type="wicri:Area/Main/Curation">003E87</idno><idno type="wicri:Area/Main/Exploration">003E87</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-dopa PET in Parkinson's disease</title><author><name sortKey="Vingerhoets, F J G" sort="Vingerhoets, F J G" uniqKey="Vingerhoets F" first="F. J. G." last="Vingerhoets">F. J. G. Vingerhoets</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre and TRIUMF, University of British Columbia</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3></inist:fA14><country>Canada</country><wicri:noRegion>Vancouver, British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Schulzer, M" sort="Schulzer, M" uniqKey="Schulzer M" first="M." last="Schulzer">M. Schulzer</name></author><author><name sortKey="Ruth, T J" sort="Ruth, T J" uniqKey="Ruth T" first="T. J." last="Ruth">T. J. Ruth</name></author><author><name sortKey="Holden, J E" sort="Holden, J E" uniqKey="Holden J" first="J. E." last="Holden">J. E. Holden</name></author><author><name sortKey="Snow, B J" sort="Snow, B J" uniqKey="Snow B" first="B. J." last="Snow">B. J. Snow</name></author></analytic><series><title level="j" type="main">The Journal of nuclear medicine : (1978)</title><title level="j" type="abbreviated">J. nucl. med. : (1978)</title><idno type="ISSN">0161-5505</idno><imprint><date when="1996">1996</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">The Journal of nuclear medicine : (1978)</title><title level="j" type="abbreviated">J. nucl. med. : (1978)</title><idno type="ISSN">0161-5505</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analysis of Variance</term><term>Brain (diagnostic imaging)</term><term>Case-Control Studies</term><term>Diagnosis</term><term>Dihydroxyphenylalanine (analogs & derivatives)</term><term>Emission tomography</term><term>Experimental study</term><term>Female</term><term>Fluorine Radioisotopes</term><term>Follow-Up Studies</term><term>Human</term><term>Humans</term><term>In vivo</term><term>Male</term><term>Measurement method</term><term>Middle Aged</term><term>Parkinson Disease (diagnostic imaging)</term><term>Parkinson Disease (epidemiology)</term><term>Parkinson disease</term><term>Positron</term><term>Reproducibility of Results</term><term>Time Factors</term><term>Tomography, Emission-Computed (methods)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Dihydroxyphenylalanine</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Brain</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Tomography, Emission-Computed</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term><term>Case-Control Studies</term><term>Female</term><term>Fluorine Radioisotopes</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Reproducibility of Results</term><term>Time Factors</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Tomoscintigraphie</term><term>Positon</term><term>Parkinson maladie</term><term>Diagnostic</term><term>Méthode mesure</term><term>Homme</term><term>In vivo</term><term>Etude expérimentale</term><term>Fluorine 18 fluorodopa</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Fluorine-18-fluorodopa (F-Dopa) PET assesses the integrity of the nigrostriatal dopaminergic neurons in Parkinson's disease. It has been used in longitudinal studies to measure the progression of Parkinson's disease and the effects of medications and intracerebral transplants. The significance of changes in PET indices in such studies depends largely on the reproducibility of the F-Dopa PET measurements. Methods : We performed repeated F-Dopa PET scans in 12 subjects with Parkinson's disease (between Hoehn and Yahr stages I and III) to measure scan-to-scan variations. Data were analyzed using five methods comprising two sets of regions of interest (ROIs) (total striatum and substriatal), the striatum-to-cortex ratio and two graphical methods (one using plasma radioactivity, the other using cortical radioactivity as the input function). We also studied the effectiveness of each method in discriminating between patients with Parkinson's disease and normal subjects using data obtained from a similar study in 10 normal subjects. Results : We found reliability coefficients between 66% and 93% ; the scan-to-scan intrasubject standard deviation ranged from 2% to 16% of the mean value depending on the method of analysis and the size of the ROls. All methods discriminated significantly between patients with Parkinson's disease and normal subjects. The ability to discriminate, as reflected by the intergroup/intragroup ratio of variance, ranged from 2 to 18. Conclusion : These results permit selection of the best method of analysis for studies of nigrostriatal dopaminergic function.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Holden, J E" sort="Holden, J E" uniqKey="Holden J" first="J. E." last="Holden">J. E. Holden</name><name sortKey="Ruth, T J" sort="Ruth, T J" uniqKey="Ruth T" first="T. J." last="Ruth">T. J. Ruth</name><name sortKey="Schulzer, M" sort="Schulzer, M" uniqKey="Schulzer M" first="M." last="Schulzer">M. Schulzer</name><name sortKey="Snow, B J" sort="Snow, B J" uniqKey="Snow B" first="B. J." last="Snow">B. J. Snow</name></noCountry><country name="Canada"><noRegion><name sortKey="Vingerhoets, F J G" sort="Vingerhoets, F J G" uniqKey="Vingerhoets F" first="F. J. G." last="Vingerhoets">F. J. G. Vingerhoets</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003E87 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003E87 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:96-0268079
|texte= Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-dopa PET in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. |  |